SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today reported its financial and operational results for the third quarter ended September 30, 2026.


Third Quarter & Subsequent 2026 Operational Highlights
In September 2026, the Company sharpened its strategy and directed the majority of its financial and personnel resources to heart attack assessment, which it views as its largest value-creation opportunity. Since then, HeartBeam has received FDA Breakthrough Device Designation, been accepted into FDA's TAP program, completed enrollment in HEADSTART-ACS, its largest heart attack assessment study to date, and reported positive pilot results from ALIGN-ACS at TCT 2026. The Company now plans to finalize the U.S. pivotal study design in the fourth quarter of 2026 and begin patient enrollment in the first quarter of 2027.
Heart Attack Assessment: Strategic Focus
Regulatory Progress
Positive Pilot Study Results Presented at TCT 2026
Key findings:
Growing Body of Clinical Evidence
Other Operational Highlights:
Management Commentary
"The third quarter marked a decisive turn for HeartBeam," said Richard Ferrari, Executive Chairman. "We committed the majority of our resources to heart attack assessment, and the milestones have quickly followed. In just the last six weeks, we received FDA Breakthrough Device Designation, were accepted into FDA's TAP program, and aligned with the FDA on a 510(k) submission pathway for a heart attack assessment indication. We also completed enrollment in HEADSTART-ACS ahead of schedule and presented positive results from the ALIGN-ACS pilot study at TCT showing higher specificity than the standard 12-lead ECG. With clinical experience in more than 600 patients and no new hardware required, we are focused on beginning our U.S. pivotal study in the first quarter of 2027."
Branislav Vajdic, Ph.D., Founder and President of HeartBeam, added, “Today, a person with chest pain at home has no reliable way to know whether it is a heart attack, and that uncertainty results in delays and potentially worse outcomes. Our goal is to shorten the time between the first sign of symptoms and the decision to seek care, by giving patients and their physicians clinical-grade cardiac information when every minute matters. We believe HeartBeam can help close that gap for the millions of people at risk.”
Third Quarter 2026 Financial Results
Selling, general and administrative expenses for the third quarter of 2026 were $1.3 million, compared to $2.0 million for the third quarter of 2025, a decrease of 33%. The decrease in SG&A expense of $0.7 million is primarily related to a decrease in non-cash stock-based compensation expense of $0.4 million and a reduction in employee costs of $0.3 million driven by lower headcount period over period.
Research and development expenses for the third quarter of 2026 were $2.1 million, compared to $3.3 million for the third quarter of 2025, a decrease of 35%. The decrease in R&D expense is primarily related to the completion of product development and consulting costs related to the HeartBeam System and a prototype patch device of $0.8 million, completion of enrollment in the ALIGN-ACS pilot study of $0.3 million, and a decrease in headcount-related costs of $0.1 million.
Total operating expenses for the third quarter of 2026 were $3.5 million, compared to $5.3 million for the third quarter of 2025.
Net loss for the third quarter of 2026 was $3.0 million, or $(0.05) per basic and diluted share, compared to a net loss of $5.3 million, or $(0.15) per basic and diluted share, for the third quarter of 2025.
Net cash used in operating activities was $2.6 million for the third quarter of 2026, a 23% decrease compared to the second quarter of 2026 and an 18% decrease compared to the third quarter of 2025. Net cash used in operating activities was $9.5 million for the nine months ended September 30, 2026, compared to $11.1 million for the nine months ended September 30, 2025, a decrease of 14%.
Cash and cash equivalents totaled $6.1 million as of September 30, 2026, compared to $4.4 million as of December 31, 2025. In August 2026, the Company entered into an at-the-market sales agreement (the “ATM”) with Titan Partners Securities LLC, as sales agent, pursuant to which the Company may sell, from time to time, shares of its common stock, par value $0.0001 per share, having an aggregate offering price of up to $25.0 million. In the fourth quarter of 2026 through the date of this release, the Company raised net proceeds of approximately $4.0 million. Giving effect to these net proceeds, the Company’s pro forma cash and cash equivalents as of September 30, 2026, would have been approximately $10.1 million.
Financial Outlook
Third Quarter 2026 Results Conference Call
HeartBeam Executive Chairman Richard Ferrari, Founder and President Branislav Vajdic, Ph.D., and Chief Financial Officer Timothy Cruickshank will host the conference call, followed by a question-and-answer period. The conference call will be accompanied by a presentation, which can be viewed during the webcast or accessed following the call via the investor relations section of the Company’s website here.
To access the call, please use the following information:
Date: | Thursday, November 12, 2026 |
Time: | 4:30 p.m. Eastern time (1:30 p.m. Pacific time) |
Dial-in: | 1-877-704-4453 |
International Dial-in: | 1-201-389-0920 |
Conference Code: | 13763268 |
Webcast: | https://viavid.webcasts.com/starthere.jsp?ei=1779198&tp_key=0e699c3be5 |
A telephone replay will be available approximately three hours after the call and will run through November 26, 2026, by dialing 1-844-512-2921 from the U.S. and Canada, or 1-412-317-6671 from international locations, and entering replay pin number: 13763268. The replay can also be viewed through the webcast link above and the presentation utilized during the call will be available in the Company’s investor relations section here.
About HeartBeam, Inc.
HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company dedicated to transforming the detection and monitoring of critical cardiac conditions. The Company has developed the first-ever cable-free device capable of collecting ECG signals in 3D, from three non-coplanar directions, and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management. HeartBeam’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, and its 12-lead ECG synthesis software received FDA clearance for arrhythmia assessment in December 2025.1 The technology is currently being studied for heart attack assessment and is considered investigational in that indication. The Company holds over 25 issued patents worldwide related to technology enablement. For additional information, visit HeartBeam.com.
Forward-Looking Statements
All statements in this release that are not based on historical fact are "forward-looking statements." While management has based any forward-looking statements included in this release on its current expectations, the information on which such expectations were based may change. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of our Forms 10-K, 10-Q and other reports filed with the SEC and available at www.sec.gov. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.
1Cleared Indications for Use |
The HeartBeam System with 12-Lead ECG synthesis software is FDA cleared for arrhythmia assessment only. The technology’s use for heart attack assessment is investigational and not FDA cleared. For full details on the intended use of the HeartBeam technology, refer to the Company’s Cleared Indications for Use and full instructions at https://www.heartbeam.com/indications. |
MKT-179 v0
HEARTBEAM, INC. Condensed Balance Sheets (Unaudited) (In thousands, except share data) | ||||||||
|
|
September 30,
|
|
December 31,
| ||||
Assets |
|
|
|
| ||||
Current Assets: |
|
|
|
| ||||
Cash and cash equivalents |
| $ | 6,065 |
|
| $ | 4,380 |
|
Prepaid expenses and other current assets |
|
| 120 |
|
|
| 202 |
|
Inventory |
|
| 114 |
|
|
| 103 |
|
Total Current Assets |
|
| 6,299 |
|
|
| 4,685 |
|
|
|
|
|
| ||||
Property and equipment, net |
|
| 1,516 |
|
|
| 1,102 |
|
Other assets |
|
| 57 |
|
|
| 56 |
|
Total Assets |
| $ | 7,872 |
|
| $ | 5,843 |
|
|
|
|
|
| ||||
Liabilities and Stockholders’ Equity |
|
|
|
| ||||
Current Liabilities: |
|
|
|
| ||||
Accounts payable (includes related party $5 and $5, respectively) |
| $ | 267 |
|
| $ | 1,053 |
|
Accrued expenses (includes related party $5 and $0, respectively) |
|
| 1,091 |
|
|
| 2,187 |
|
Total Current Liabilities |
|
| 1,358 |
|
|
| 3,240 |
|
|
|
|
|
| ||||
Total Liabilities |
|
| 1,358 |
|
|
| 3,240 |
|
|
|
|
|
| ||||
Commitments and Contingencies (Note 8) |
|
|
|
| ||||
|
|
|
|
| ||||
Stockholders’ Equity |
|
|
|
| ||||
Preferred stock - $0.0001 par value; 10,000,000 shares authorized; 0 shares outstanding at September 30, 2026 and December 31, 2025 |
| $ | — |
|
| $ | — |
|
Common stock - $0.0001 par value; 100,000,000 shares authorized; 57,513,001 and 40,117,404 shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively |
|
| 6 |
|
|
| 4 |
|
Additional paid in capital |
|
| 96,545 |
|
|
| 79,887 |
|
Accumulated deficit |
|
| (90,037 | ) |
|
| (77,288 | ) |
Total Stockholders’ Equity |
|
| 6,514 |
|
|
| 2,603 |
|
|
|
|
|
| ||||
Total Liabilities and Stockholders’ Equity |
| $ | 7,872 |
|
| $ | 5,843 |
|
HEARTBEAM, INC. Condensed Statements of Operations (Unaudited) (In thousands, except share and per share data) | ||||||||||||||||
|
|
Three months ended
|
|
Nine months ended
| ||||||||||||
|
|
| 2026 |
|
|
| 2025 |
|
|
| 2026 |
|
|
| 2025 |
|
Operating Expenses: |
|
|
|
|
|
|
|
| ||||||||
Selling, general and administrative |
| $ | 1,339 |
|
| $ | 2,012 |
|
| $ | 6,449 |
|
| $ | 5,733 |
|
Research and development |
|
| 2,118 |
|
|
| 3,278 |
|
|
| 6,816 |
|
|
| 10,096 |
|
Total operating expenses |
|
| 3,457 |
|
|
| 5,290 |
|
|
| 13,265 |
|
|
| 15,829 |
|
Loss from operations |
|
| (3,457 | ) |
|
| (5,290 | ) |
|
| (13,265 | ) |
|
| (15,829 | ) |
Other Income and (Expense) |
|
|
|
|
|
|
|
| ||||||||
Interest income |
|
| 63 |
|
|
| 36 |
|
|
| 135 |
|
|
| 117 |
|
Other income, net |
|
| 384 |
|
|
| (1 | ) |
|
| 381 |
|
|
| (1 | ) |
Total other income |
|
| 447 |
|
|
| 35 |
|
|
| 516 |
|
|
| 116 |
|
Loss before provision for income taxes |
|
| (3,010 | ) |
|
| (5,255 | ) |
|
| (12,749 | ) |
|
| (15,713 | ) |
Income tax provision |
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
Net Loss |
| $ | (3,010 | ) |
| $ | (5,255 | ) |
| $ | (12,749 | ) |
| $ | (15,713 | ) |
Net loss per share, basic and diluted |
| $ | (0.05 | ) |
| $ | (0.15 | ) |
| $ | (0.25 | ) |
| $ | (0.48 | ) |
Weighted average common shares outstanding, basic and diluted |
|
| 57,204,402 |
|
|
| 34,396,431 |
|
|
| 50,242,536 |
|
|
| 32,928,884 |
|
HEARTBEAM, INC. Condensed Statements of Cash Flows (Unaudited) (In thousands) | ||||||||
|
| Nine months ended September 30, | ||||||
|
|
| 2026 |
|
|
| 2025 |
|
Cash Flows From Operating Activities |
|
|
|
| ||||
Net loss |
| $ | (12,749 | ) |
| $ | (15,713 | ) |
Adjustments to reconcile net loss to net cash used in operating activities |
|
|
|
| ||||
Depreciation |
|
| 150 |
|
|
| 23 |
|
Stock based compensation expense |
|
| 3,855 |
|
|
| 3,720 |
|
Stock issuance upon vesting of restricted stock units |
|
| 915 |
|
|
| — |
|
Stock issuance for services |
|
| 100 |
|
|
| — |
|
Changes in operating assets and liabilities: |
|
|
|
| ||||
Prepaid expenses and other current assets |
|
| 82 |
|
|
| 123 |
|
Inventory |
|
| (11 | ) |
|
| — |
|
Accounts payable and accrued expenses |
|
| (1,882 | ) |
|
| 765 |
|
Net cash used in operating activities |
|
| (9,540 | ) |
|
| (11,082 | ) |
|
|
|
|
| ||||
Cash Flows From Investing Activities |
|
|
|
| ||||
Purchase of property and equipment |
|
| (564 | ) |
|
| (184 | ) |
Purchase of short-term investments |
|
| — |
|
|
| 3,760 |
|
Maturities of short-term investments |
|
| — |
|
|
| (3,760 | ) |
Net cash used in investing activities |
|
| (564 | ) |
|
| (184 | ) |
|
|
|
|
| ||||
Cash Flows From Financing Activities |
|
|
|
| ||||
Proceeds from sale of equity, net of issuance costs |
|
| 10,265 |
|
|
| 10,250 |
|
Proceeds from sale of equity under ATM, net of issuance costs |
|
| 1,515 |
|
|
| 494 |
|
Proceeds from exercise of stock options |
|
| 10 |
|
|
| 1 |
|
Net cash provided by financing activities |
|
| 11,790 |
|
|
| 10,745 |
|
|
|
|
|
| ||||
Net increase / (decrease) in cash and restricted cash |
|
| 1,686 |
|
|
| (521 | ) |
Cash, cash equivalents and restricted cash – Beginning of period |
|
| 4,436 |
|
|
| 2,433 |
|
|
|
|
|
| ||||
Cash, cash equivalents and restricted cash – Ending of period |
| $ | 6,122 |
|
| $ | 1,912 |
|
|
|
|
|
| ||||
Reconciliation of cash, cash equivalents and restricted cash: |
|
|
|
| ||||
Cash and cash equivalents |
| $ | 6,065 |
|
| $ | 1,856 |
|
Restricted cash (included in other assets) |
|
| 57 |
|
|
| 56 |
|
Total cash, cash equivalents and restricted cash |
| $ | 6,122 |
|
| $ | 1,912 |
|
|
|
|
|
| ||||
Supplemental Disclosures of Cash Flow Information: |
|
|
|
| ||||
Purchase of property and equipment in accounts payable |
| $ | — |
|
| $ | 83 |
|
Taxes paid |
| $ | — |
|
| $ | — |
|
Media Contact:
media@heartbeam.com
Investor Relations Contact:
Chris Tyson
Executive Vice President
MZ North America
Direct: 949-491-8235
BEAT@mzgroup.us
www.mzgroup.us
| Nov-12 | |
| Nov-12 | |
| Nov-04 | |
| Nov-03 | |
| Nov-02 | |
| Oct-28 | |
| Oct-26 | |
| Oct-21 | |
| Oct-15 | |
| Oct-05 | |
| Oct-05 | |
| Sep-21 | |
| Aug-14 | |
| Aug-13 | |
| Aug-12 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, alerts, and much more.
Learn more about Finviz Elite